Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

OTLKW

Outlook Therapeutics (OTLKW)

Outlook Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:OTLKW
DataHoraFonteTítuloCódigoCompanhia
11/06/202410:05GlobeNewswire Inc.Outlook Therapeutics® to Present at the Virtual Investor Pitch ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
28/05/202409:05GlobeNewswire Inc.Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
15/05/202418:00GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKWOutlook Therapeutics Inc
13/05/202409:50GlobeNewswire Inc.Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
09/05/202409:45GlobeNewswire Inc.Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastNASDAQ:OTLKWOutlook Therapeutics Inc
02/05/202410:05GlobeNewswire Inc.Outlook Therapeutics® to Present at the Retina World Congress 2024NASDAQ:OTLKWOutlook Therapeutics Inc
29/04/202410:00GlobeNewswire Inc.Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseNASDAQ:OTLKWOutlook Therapeutics Inc
15/04/202417:15GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionNASDAQ:OTLKWOutlook Therapeutics Inc
22/03/202408:35GlobeNewswire Inc.Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
18/03/202418:10GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of up to $159 MillionNASDAQ:OTLKWOutlook Therapeutics Inc
12/03/202409:05GlobeNewswire Inc.Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock SplitNASDAQ:OTLKWOutlook Therapeutics Inc
14/02/202410:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKWOutlook Therapeutics Inc
31/01/202410:05GlobeNewswire Inc.Outlook Therapeutics® Doses First Subject in NORSE EIGHTNASDAQ:OTLKWOutlook Therapeutics Inc
23/01/202410:00GlobeNewswire Inc.Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010NASDAQ:OTLKWOutlook Therapeutics Inc
22/12/202310:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EUNASDAQ:OTLKWOutlook Therapeutics Inc
19/12/202310:05GlobeNewswire Inc.Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010NASDAQ:OTLKWOutlook Therapeutics Inc
06/12/202310:05GlobeNewswire Inc.Outlook Therapeutics® Announces Strategic Organizational RealignmentNASDAQ:OTLKWOutlook Therapeutics Inc
27/11/202310:05GlobeNewswire Inc.Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010NASDAQ:OTLKWOutlook Therapeutics Inc
14/11/202310:05GlobeNewswire Inc.Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of EuropeNASDAQ:OTLKWOutlook Therapeutics Inc
02/11/202309:05GlobeNewswire Inc.Outlook Therapeutics® Provides Update on Type A Meetings with FDANASDAQ:OTLKWOutlook Therapeutics Inc
01/11/202309:05GlobeNewswire Inc.Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
29/09/202309:05GlobeNewswire Inc.Outlook Therapeutics® Requests Type A Meeting With FDANASDAQ:OTLKWOutlook Therapeutics Inc
21/09/202309:05GlobeNewswire Inc.Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
05/09/202309:05GlobeNewswire Inc.Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
30/08/202307:00GlobeNewswire Inc.Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
14/08/202309:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term MilestonesNASDAQ:OTLKWOutlook Therapeutics Inc
01/08/202309:45GlobeNewswire Inc.Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023NASDAQ:OTLKWOutlook Therapeutics Inc
16/05/202308:10Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:OTLKWOutlook Therapeutics Inc
16/05/202307:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OTLKWOutlook Therapeutics Inc
15/05/202309:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate UpdateNASDAQ:OTLKWOutlook Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:OTLKW